Encoded Therapeutics Presents Updated Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the 16th European Epilepsy Congress

Encoded Therapeutics presented updated Phase 1/2 POLARIS trial data for its ETX101 gene therapy candidate in Dravet syndrome at the European Epilepsy Congress. The article provides no efficacy, safety, or financial results, limiting assessment of the program's clinical or valuation impact.